Does it excite you to work with market analytics and competitive intelligence, and do you have deep experience with U.S. pharmaceutical market data? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As Associate Director, Market Analytics, you will shape our insights agenda for upcoming launches in obesity and rare diseases (petrelintide, SBS, CHI). You will drive comprehensive market analysis and competitive intelligence to inform go-to-market strategy, launch execution, and long-range business planning across our portfolio. You will bring deep expertise in secondary market data analytics and U.S. market dynamics, and act as a strategic thought partner to commercial leadership.
We offer exciting responsibilities:
You are an experienced market analytics professional who thrives on ambiguity and brings analytical rigor and business acumen to fast-paced, dynamic environments. You are a strong communicator who can distill complex data into clear recommendations for senior stakeholders, and you're motivated to help shape strategy for upcoming launches.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
Salary Range: $158,000 - $218,000/Yr
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cabridge, Massachusetts. Learn more at www.zealandpharma.com.
At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
